On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
Key facts
Extracted from this filing and checked against the source text.
Earnings ReleasesSEC 8-K Item 2.02confidence 0.9
Anika Therapeutics, Inc. reported first quarter 2026 results: revenue $29.6 million, net income $5.1 million loss, EPS ($0.37) per diluted share.
Period
first quarter 2026
Revenue
$29.6 million
Net income
$5.1 million loss
EPS
($0.37) per diluted share
Result
reported results
Exact text from the filing
First Quarter 2026 Continuing Operations Financial Summary Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share
Anika Therapeutics, Inc. reported fiscal year 2026 results: revenue $114 to $122.5 million. Guidance reaffirmed.
Period
fiscal year 2026
Revenue
$114 to $122.5 million
Guidance
reaffirmed
Result
guidance update
Exact text from the filing
Fiscal 2026 Guidance Anika is maintaining the previously provided 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year OEM Channel, $61 to $64.5 million, flat to modestly lower year over year Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.
William R. Jellison resigned as Class I member of the Board of Directors at Anika Therapeutics, Inc..
Action
resigned
Role
Class I member of the Board of Directors
Exact text from the filing
On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
Glenn R. Larsen resigned as Class II member of the Board at Anika Therapeutics, Inc..
Action
resigned
Role
Class II member of the Board
Exact text from the filing
On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.